



Ki67 (2641-2940): sc-4359 WB

BACKGROUND

Ki67 is a nuclear protein that is expressed in proliferating cells and may be required for maintaining cell proliferation. Ki67 has been used as a marker for cell proliferation of solid tumors and some hematological malignancies. A correlation has been demonstrated between Ki67 index and the histopathological grade of neoplasms. Assessment of Ki67 expression in renal and ureter tumors shows a correlation between tumor proliferation and disease progression, thus making it possible to differentiate high-risk patients. Ki67 expression may also prove to be important for distinguishing between malignant and benign peripheral nerve sheath tumors.

REFERENCES

1. Lopez, F., Belloc, F., Lacombe, F., Dumain, P., Reiffers, J., Bernard, P., and Boisseau, M.R. 1991. Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. *Cytometry* 12: 42-49.
2. Schluter, C., Duchrow, M., Wohlenberg, C., Becker, M.H., Key, G., Flad, H.D., and Gerdes, J. 1993. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. *J. Cell Biol.* 123: 513-522.
3. Gore, S.D., Weng, L.J., and Burke, P.J. 1993. Validation of flow-cytometric determination of Ki67 expression as a measure of growth factor response in acute myelogenous leukemia. *Exp. Hematol.* 21: 1702-1708.
4. Limas, C., Bigler, A., Bair, R., Bernhart, P., and Reddy, P. 1993. Proliferation activity of urothelial neoplasms: comparison of BrdU incorporation, Ki67 expression, and nucleolar organizer regions. *J. Clin. Pathol.* 46: 159-165.
5. Kindblom, L.G., Ahlden, M., Meis-Kindblom, J.M., Stenman, G. 1995. Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumors. *Virchows. Arch.* 427: 19-26.
6. Rey, A., Lara, P.C., Redondo, E., Valdes, E., and Apolinario, R. 1998. Ki67 proliferation index in tumors of the upper urinary tract as related to established prognostic factors and long-term survival. *Arch. Esp. Urol.* 51: 204-210.
7. Pollack, A., Cowen, D., Troncoso, P., Zagars, G.K., von Eschenbach, A.C., Meistrich, M.L., McDonnell, T. 2003. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, Bcl-2, bax, and Bcl-x. *Cancer* 97: 1630-1638.
8. Koyamatsu, Y., Yokoyama, M., Nakao, Y., Fukuda, K., Saito, T., Matsukuma, K., Iwasaka, T. 2003. A comparative analysis of human papillomavirus types 16 and 18 and expression of p53 gene and Ki-67 in cervical, vaginal, and vulvar carcinomas. *Gynecol. Oncol.* 90: 547-551.
9. Siironen, P., Nordling, S., Louhimo, J., Haapiainen, R., Haglund, C. 2005. Immunohistochemical expression of Bcl-2, Ki-67, and p21 in patients with papillary thyroid cancer. *Tumour. Biol.* 26: 50-56.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

SOURCE

Ki67 (2641-2940) is expressed in *E. coli* as a 62 kDa tagged fusion protein corresponding to amino acids 2641-2940 mapping at the carboxy terminus of Ki67 of human origin.

PRODUCT

Ki67 (2641-2940) is purified from bacterial lysates (> 98%) by column chromatography; supplied as 10 µg in 0.1 ml SDS-PAGE loading buffer.

APPLICATIONS

Ki67 (2641-2940) is suitable as a Western blotting control for sc-7844, sc-7846, sc-15402 and sc-17782.

STORAGE

Store at -20° C; stable for one year from the date of shipment.

RESEARCH USE

For research use only, not for use in diagnostic procedures.